Welcome to our dedicated page for Valion Bio news (Ticker: VBIO), a resource for investors and traders seeking the latest updates and insights on Valion Bio stock.
Valion Bio, Inc. reports company developments tied to its TLR5 agonist immunotherapeutic pipeline, including Entolimod™ for Acute Radiation Syndrome and oncology supportive care and Entolasta™ as a next-generation TLR5 agonist. Recurring updates include financial results, business updates, FDA pathway and designation references, government and biodefense engagement, and clinical-development positioning for supportive-care indications.
Valion Bio news also covers its completed rebranding from Tivic Health Systems, the Nasdaq ticker change to VBIO, leadership and legal-governance appointments, and activity at Velocity Bioworks, the company's wholly owned CDMO subsidiary in San Antonio.
Vitality Biopharma (VBIO) announced a $5 million equity line financing with an institutional investor.
This financing will allow the company to sell shares up to $250,000 per purchase notice until December 31, 2022, at 85% of the stock's lowest daily volume weighted average price over the prior five days.
The funds are earmarked for advancing the prodrug candidate VBX-100, which recently received Orphan Drug Designation from the FDA for pediatric ulcerative colitis.
On August 10, 2021, Vitality Biopharma (OTC: VBIO) received Orphan Drug Designation from the FDA for its glycosylated cannabinoid prodrug VBX-100, aimed at treating pediatric ulcerative colitis. This milestone highlights the company's commitment to developing innovative treatments for gastrointestinal disorders. With a portfolio of over 100 cannabinoid compounds, Vitality plans to expedite research and capitalize on the benefits of orphan designation, including seven years of market exclusivity and tax incentives for clinical trials.